Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04470427 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
A Phase 3 study of SARS-CoV-2, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 30,415
- Enrollment target
- 20
- Study locations
NCT04470427: Completed Phase 3 study of SARS-CoV-2, sponsored by ModernaTX.
NCT04470427 is a Phase 3 study of SARS-CoV-2 that has completed, run by ModernaTX. The registered enrollment target is 30,415 participants, above the 2,560-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (1088% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04470427, a Phase 3 study of SARS-CoV-2, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30,415 participants
- Enrollment target
- 20
- Study locations
Study Summary
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
Primary Outcome
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1273
Study Locations (20)
California
- Advanced Clinical Research - Rancho Paseo - Banning
- University of California San Diego - La Jolla
- eStudySite - La Mesa - La Mesa
- UCLA Vine Street Clinic CRS - Los Angeles
- VA Greater Los Angeles Healthcare (veterans only) - Los Angeles
- Paradigm Clinical Research Institute Inc - Redding
- Benchmark Research - Sacramento - Sacramento
- Medical Center For Clinical Research - M3 Wake Research - San Diego
Arizona
- Hope Research Institute - Chandler
- Synexus Clinical Research US, Inc. - Phoenix West - Glendale
- Hope Research Institute - Peoria
- Hope Research Institute - Phoenix
- Quality of Life Medical and Research Center - Tucson
Alabama
- Ascension St. Vincent Birmingham - Birmingham
- Synexus Clinical Research US, Inc. - Birmingham - Birmingham
Colorado
- University of Colorado Hospital - Aurora
- Lynn Institute of The Rockies - Colorado Springs
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
District of Columbia
- George Washington University - Washington D.C.
Florida
- Accel Research Site - DeLand
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,415 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2022-12-29 |
| Phase | Phase 3 |
What the finished NCT04470427 record still lists
NCT04470427 is an interventional study that assigns participants to a tested intervention. Its 30,415 participants enrollment target places it among the larger protocols in the corpus, above the 2,560-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (1088% higher).
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04470427 names 20 study sites across 7 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT04470427 about?
NCT04470427 is a clinical study titled "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after...
What is the current status of trial NCT04470427?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30,415 participants. The study started on 2020-07-27. Estimated completion is 2022-12-29.
What conditions does trial NCT04470427 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT04470427?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04470427?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04470427 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04470427's enrollment target sits among peer trials
30,415 2nd of 34 the highest of 34 other SARS-CoV-2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV-2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
COMPLETED · Phase 3
-
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
COMPLETED · Phase 3
-
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
COMPLETED · Phase 3
-
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
COMPLETED · Phase 3
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI